About Biosergen
Biosergen is a company based in Solna (Sweden) founded in 2004. It operates as a HealthTech. Biosergen offers products and services including BSG005. Biosergen operates in a competitive market with competitors including Scynexis, F2g, Amplyx Pharmaceuticals, Elion Therapeutics and Viamet Pharmaceuticals, among others.
- Headquarter Solna, Sweden
- Stage Minicorn
-
Sectors
Healthcare
-
Phone
Locked
-
Website
Locked
- Legal Name Biosergen Ab
-
Annual Revenue
Not available
-
Net Profit
Not available
-
EBITDA
Not available
-
Latest Funding Round
Not available
-
Investors
Rosetta Capital
& 1 more
-
Employee Count
Not available
Unlock complete access to The Company Check
Get unrestricted viewing across everything we track — from companies and brands to investors, funding rounds, acquisitions, financials, and more.
- Unlimited viewing on all profiles Companies, investors, financials, funding, acquisitions & directors
- Full access to every database India & global coverage, advanced filters and rich profile details
- Always-on access from your team account Single premium plan for everything you see on the portal
Products & Services of Biosergen
Biosergen offers a comprehensive portfolio of products and services, including BSG005.
BSG005 is developed as an innovative antifungal treatment.
Funding Insights of Biosergen
Investors in Biosergen
Biosergen has secured backing from 2 investors, including venture fund investors. Prominent investors backing the company include Rosetta Capital and BtoV.
| Investor | Description | Founded Year | Domain | Location |
|---|---|---|---|---|
|
Venture capital investment firm
|
Locked | Locked | Locked | |
|
Stage agnostic VC firm funding companies in Europe
|
Locked | Locked | Locked |
Investor details for Biosergen
Investor domains, locations, round participation, and complete history require an active premium plan.
- Investor domains
- Investor locations
- Funding rounds
- Participation history
Verified entity values are shown only after access is granted.
Investments & Acquisitions by Biosergen
Investment portfolio details for Biosergen
Portfolio company identities, transaction dates, round details, and investment values require an active premium plan.
- Portfolio identities
- Transaction dates
- Round details
- Investment values
Verified entity values are shown only after access is granted.
Financial Statements - Biosergen
Detailed financials for Biosergen
Historical revenue, profit, statement rows, ratios, and trend charts require an active premium plan.
- Historical revenue
- Profit trends
- Statement rows
- Financial ratios
Verified entity values are shown only after access is granted.
Biosergen Comparisons
Peer comparison for Biosergen
Named peer metrics, headcount, funding, location, and side-by-side benchmarks require an active premium plan.
- Named peers
- Headcount comparison
- Funding comparison
- Operating benchmarks
Verified entity values are shown only after access is granted.
Competitors of Biosergen
Biosergen operates in a dynamic and competitive business environment, facing competition from various established players and emerging companies in the market. The competitive landscape includes prominent companies such as Scynexis, F2g, Amplyx Pharmaceuticals, Elion Therapeutics and Viamet Pharmaceuticals, among others.
| Company Name | Domain | Founded year | HQ Location | Description |
|---|---|---|---|---|
| Locked | Locked | Locked |
Developing glucan synthase inhibitors for the treatment of fungal infections.
|
|
| Locked | Locked | Locked |
Drugs for systemic fungal diseases are discovered and developed.
|
|
| Locked | Locked | Locked |
Broad-spectrum fungal enzyme inhibitors are developed by clinical-stage biopharma.
|
|
| Locked | Locked | Locked |
Therapeutics for invasive fungal infections are developed by Elion Therapeutics.
|
|
| Locked | Locked | Locked |
Therapies for chronic fungal infections are developed using metalloenzyme inhibitors.
|
Detailed competitors of Biosergen
Competitor domains, locations, full profiles, and operating metrics require an active premium plan.
- Domains and locations
- Full company profiles
- Operating metrics
- Competitive positioning
Verified entity values are shown only after access is granted.
Latest news on Biosergen
Complete news archive for Biosergen
Full article history, source details, and older brand coverage require an active premium plan.
- Full article archive
- Source and publication date
- Older coverage
- Brand-specific news history
Verified entity values are shown only after access is granted.
Frequently Asked Questions about Biosergen
Biosergen was founded in 2004 and raised its 1st funding round 9 years after it was founded.
Biosergen is headquartered in Solna, Sweden.
Peder M Andersen is the current CEO of Biosergen.
Biosergen is engaged in the development of groundbreaking antifungal drugs, with a primary focus on their lead product, BSG005. This drug is designed to offer superior safety and potency for treating invasive fungal infections in immunocompromised patients, including those with AIDS, cancer, and transplant recipients. The company operates in the healthcare and biotechnology sector, providing solutions to address life-threatening fungal diseases recognized as a global health threat by WHO. Research and development are conducted in collaboration with institutions like the Norwegian University of Science and Technology and SINTEF in Norway, alongside global partnerships such as with Alkem Laboratories in India.
Biosergen's top competitors include Scynexis, F2g and Amplyx Pharmaceuticals.
Biosergen offers BSG005.
Biosergen has 2 investors. Key investors include Rosetta Capital, and BtoV.
The valuation of Biosergen is $9.44M as of Feb 2016.